Novartis (NVS) announced that a Phase 3 study evaluating BAF312 (siponimod) for the treatment of secondary progressive multiple sclerosis (SPMS) met its primary endpoint of a reduction in the risk of disability progression versus placebo. Top-line data will be presented on September 17 at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis in London. The primary efficacy endpoint was an improvement in the time to three-month confirmed disability progression measured by a scale called EDSS (expanded disability status scale) compared to placebo.